Cascadian Therapeutics (ONTY) 10-Q 6 Nov 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 06, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Oncothyreon Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	91,555,975
Amendment Flag	'false	'
Entity Central Index Key	'0001412067	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Accelerated Filer	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (current period unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current:	'	'
Cash and cash equivalents	$34,242	$9,279
Short-term investments	46,520	50,748
Accounts and other receivables	309	197
Prepaid and other current assets	887	720
Total current assets	81,958	60,944
Long-term investments	10,483	12,535
Property and equipment, net	1,655	1,695
Indefinite-lived intangible assets	19,738	'
Goodwill	16,659	2,117
Other assets	453	455
Total assets	130,946	77,746
Current:	'	'
Accounts payable	303	533
Accrued and other liabilities	3,028	2,622
Accrued compensation and related liabilities	1,222	1,311
Current portion of restricted share unit liability	156	194
Total current liabilities	4,709	4,660
Deferred rent	363	439
Restricted share unit liability	157	143
Warrant liability	383	924
Deferred tax liability	6,908	'
Class UA preferred stock, 12,500 shares authorized, 12,500 shares issued and outstanding	30	30
Commitments and contingencies	'	'
Stockholders’ equity:	'	'
Series A Convertible Preferred Stock – 10,000 shares and zero shares as of September 30, 2014 and December 31, 2013, respectively	0	0
Common stock, $0.0001 par value; 200,000,000 shares and 100,000,000 shares authorized as of September 30, 2014 and December 31, 2013, respectively; 91,555,975 shares and 70,673,143 shares issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	353,856	353,854
Additional paid-in capital	224,059	154,832
Accumulated deficit	-454,469	-432,085
Accumulated other comprehensive loss	-5,050	-5,051
Total stockholders’ equity	118,396	71,550
Total liabilities and stockholders’ equity	$130,946	$77,746

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (current period unaudited) (Parentheticals) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Class UA preferred stock, shares authorized, issued and outstanding	12,500	12,500
Preferred stock par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	10,000	10,000
Preferred stock, shares outstanding	0	0
Common stock par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	200,000,000	100,000,000
Common stock, shares issued	91,555,975	70,673,143
Common stock, shares outstanding	91,555,975	70,673,143

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Operating expenses	'	'	'	'
Research and development	$5,663	$5,517	$15,876	$27,374
General and administrative	2,357	2,085	7,101	6,266
Total operating expenses	8,020	7,602	22,977	33,640
Loss from operations	-8,020	-7,602	-22,977	-33,640
Other income (expenses)	'	'	'	'
Investment and other income (expenses), net	11	66	52	118
Change in fair value of warrant liability	1,273	-174	541	1,126
Total other income (expenses), net	1,284	-108	593	1,244
Net loss	($6,736)	($7,710)	($22,384)	($32,396)
Net loss per share—basic and diluted (in Dollars per share)	($0.09)	($0.12)	($0.31)	($0.54)
Shares used to compute basic and diluted net loss per share (in Shares)	77,237,246	63,886,874	72,919,829	59,962,328

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net loss	($6,736)	($7,710)	($22,384)	($32,396)
Available-for-sale securities:	'	'	'	'
Unrealized gain (loss) during the period, net	-1	22	1	1
Other comprehensive income (loss)	-1	22	1	1
Comprehensive loss	($6,737)	($7,688)	($22,383)	($32,395)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities	'	'
Net loss	($22,384)	($32,396)
Depreciation and amortization	373	367
Amortization of premiums and accretion of discounts on securities	443	473
Share-based compensation expense	1,751	1,628
Change in fair value of warrant liability	-541	-1,126
Cash settled on conversion of restricted share units	-96	-11
Other	-1	-45
Accounts and other receivable	-112	84
Prepaid expenses and other current assets	-167	-208
Other long term assets	2	-132
Accounts payable	-230	-456
Accrued and other liabilities	162	1,068
Accrued compensation and related liabilities	-89	23
Deferred rent	-76	-70
Net cash used in operating activities	-20,965	-30,801
Cash flows from investing activities	'	'
Purchases of investments	-34,007	-50,190
Redemption of investments	39,847	52,066
Purchases of property and equipment, net	-332	-253
Cash assumed in connection with the acquisition of Alpine Bioscience, Inc.	104	'
Net cash provided by investing activities	5,612	1,623
Cash flows from financing activities	'	'
Proceeds from issuance of common stock, net of issuance cost	21,622	19,686
Proceeds from issuance of convertible preferred stock, net of issuance cost	18,693	'
Proceeds from stock options exercised	1	'
Net cash provided by financing activities	40,316	19,686
Increase (decrease) in cash and cash equivalents	24,963	-9,492
Cash and cash equivalents, beginning of period	9,279	22,266
Cash and cash equivalents, end of period	34,242	12,774
Non-cash activities	'	'
Issuance of common stock in connection with the acquisition of Alpine	$27,233	'

Note_1_Description_of_Business

Note 1 - Description of Business	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Nature of Operations [Text Block]	'
	1.        DESCRIPTION OF BUSINESS
	Oncothyreon Inc. (the Company) is a clinical-stage biopharmaceutical company incorporated in the State of Delaware on September 7, 2007. The Company is focused primarily on the development of therapeutic products for the treatment of cancer. The Company’s goal is to discover, develop and commercialize compounds that have the potential to improve the lives and outcomes of cancer patients. The Company’s operations are not subject to any seasonality or cyclicality factors.

Note_2_Basis_of_Presentation

Note 2 - Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Basis of Presentation and Significant Accounting Policies [Text Block]	'
	2.        BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial statements. The accounting principles and methods of computation adopted in these condensed consolidated financial statements are the same as those of the audited consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities Exchange Commission (the SEC) on March 13, 2014.
	Omitted from these statements are certain information and note disclosures normally included in the audited consolidated financial statements prepared in accordance with U.S. GAAP. The Company believes all adjustments necessary for a fair statement of the results for the periods presented have been made, and such adjustments consist only of those considered normal and recurring in nature. The financial results for the three and nine months ended September 30, 2014 are not necessarily indicative of financial results for the full year. The condensed consolidated balance sheet as of December 31, 2013 has been derived from the audited financial statements at that date. The unaudited condensed consolidated financial statements and notes presented should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 13, 2014.
	Accumulated Other Comprehensive Income (Loss)
	Comprehensive income or loss is comprised of net income or loss and other comprehensive income or loss. Other comprehensive income or loss includes unrealized gains and losses on the Company’s available-for-sale investments. In addition to unrealized gains and losses on investments, accumulated other comprehensive income or loss consists of foreign currency translation adjustments which arose from the conversion of the Canadian dollar functional currency consolidated financial statements to the U.S. dollar reporting currency consolidated financial statements prior to January 1, 2008. Should the Company liquidate or substantially liquidate its investments in its foreign subsidiaries, the Company would be required to recognize the related cumulative translation adjustments pertaining to the liquidated or substantially liquidated subsidiaries, as a charge to earnings in the Company’s condensed consolidated statements of operations and comprehensive loss.
	There were no reclassifications out of accumulated other comprehensive loss during the three and nine months ended September 30, 2014. The tables below show the changes in accumulated balances of each component of accumulated other comprehensive loss for the three and nine months ended September 30, 2014 and September 30, 2013:
		Three months ended September 30, 2014
		Net unrealized gains/(losses) on Available-for-sale Securities			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Loss
		(In thousands)
	Balance at July 1, 2014	$	17		$	(5,066	)	$	(5,049	)
	Current period other comprehensive loss		(1	)		—			(1	)
	Balance at September 30, 2014	$	16		$	(5,066	)	$	(5,050	)
		Nine months ended September 30, 2014
		Net unrealized gains/(losses) on Available-for-sale Securities			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Loss
		(In thousands)
	Balance at December 31, 2013	$	15		$	(5,066	)	$	(5,051	)
	Current period other comprehensive income		1			—			1
	Balance at September 30, 2014	$	16		$	(5,066	)	$	(5,050	)
		Three months ended September 30, 2013
		Net unrealized gains/(losses) on Available-for-sale Securities			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Loss
		(In thousands)
	Balance at July 1, 2013	$	9		$	(5,066	)	$	(5,057	)
	Current period other comprehensive income		22			—			22
	Balance at September 30, 2013	$	31		$	(5,066	)	$	(5,035	)
		Nine months ended September 30, 2013
		Net unrealized gains/(losses) on Available-for-sale Securities			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Loss
		(In thousands)
	Balance at December 31, 2012	$	30		$	(5,066	)	$	(5,036	)
	Current period other comprehensive income		1			—			1
	Balance at September 30, 2013	$	31		$	(5,066	)	$	(5,035	)

Note_3_Recent_Accounting_Prono

Note 3 - Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	'
	3.       RECENT ACCOUNTING PRONOUNCEMENTS
	In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. This standard applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact this standard will have on the consolidated financial position or results of operations.
	In May 2014, FASB issued Accounting Standard Update 2014-09, Revenue from Contracts with Customers (Topic 606) that will supersede most revenue recognition standards. Under the new standard, an entity will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the payment to which the entity expects to be entitled in exchange for those goods or services. An entity would recognize revenue through a five-step process: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. This standard also requires enhanced disclosures and provides more comprehensive guidance for transactions such as service revenue and contract modifications. Guidance for multiple-element arrangements also has been enhanced. The standard will take effect for public entities for annual reporting periods beginning after December 15, 2016, including interim reporting periods. Early application is not permitted. The Company is currently evaluating the impact this standard will have on the consolidated financial position or results of operations.
	In July 2013, FASB issued guidance on presentation of an unrecognized tax benefit in financial statements when a net operating loss (NOL) carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for an NOL carryforward, or similar tax loss or tax credit carryforward, rather than as a liability when (1) the uncertain tax position would reduce the NOL or other carryforward under the tax law of the applicable jurisdiction and (2) the entity intends to use the deferred tax asset for that purpose. The guidance does not require new recurring disclosures. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013 for public entities. Early adoption and retrospective application are permitted. The Company adopted this standard on January 1, 2014. The adoption of this standard had no impact on the presentation of the Company’s unrecognized tax benefits or on the consolidated financial position or results of operations.

Note_4_Fair_Value_Measurements

Note 4 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	4.       FAIR VALUE MEASUREMENTS
	The Company measures certain financial assets and liabilities at fair value in accordance with a hierarchy which requires an entity to maximize the use of observable inputs which reflect market data obtained from independent sources and minimize the use of unobservable inputs which reflect the Company’s market assumptions when measuring fair value. There are three levels of inputs that may be used to measure fair value:
		•	Level 1—quoted prices in active markets for identical assets or liabilities;
		•	Level 2—observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
		•	Level 3—unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s financial assets and liabilities measured at fair value consisted of the following as of September 30, 2014 and December 31, 2013:
			30-Sep-14								31-Dec-13
			Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
			(In thousands)
	Financial assets:
	Money market funds		$	29,280	$	—	$	—	$	29,280	$	6,058	$	—	$	—	$	6,058
	Debt securities of U.S. government agencies			—		41,936		—		41,936		—		49,890		—		49,890
	Corporate bonds			—		15,067		—		15,067		—		13,393		—		13,393
			$	29,280	$	57,003	$	—	$	86,283	$	6,058	$	63,283	$	—	$	69,341
	Financial liabilities:
	Restricted share units		$	313	$	—	$	—	$	313	$	337	$	—	$	—	$	337
	Warrants		$	—	$	—	$	383	$	383	$	—	$	—	$	924	$	924
	If quoted market prices in active markets for identical assets are not available to determine fair value, then the Company uses quoted prices of similar instruments and other significant inputs derived from observable market data obtained from third-party data providers. These investments are included in Level 2 and consist of debt securities of U.S government agencies and corporate bonds. There were no transfers between Levels 1 and 2 during the three and nine month period ended September 30, 2014. The Company classifies its warrant liability within Level 3 because the warrant liability is valued using valuation models with significant unobservable inputs. The estimated fair value of warrants accounted for as liabilities was determined on the issuance date and are subsequently remeasured to fair value at each reporting date. The change in fair value of the warrants is recorded in the statement of operations as other income or other expense estimated by using the Black-Scholes option-pricing model. A discussion of the valuation techniques and inputs to determine fair value of these instruments is included in Note 9.

Note_5_Financial_Instruments

Note 5 - Financial Instruments	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Financial Instruments Disclosure [Text Block]	'
	5.       FINANCIAL INSTRUMENTS
	Financial instruments consist of cash and cash equivalents, investments and accounts and other receivables that will result in future cash receipts, as well as accounts payable, accrued and other liabilities, restricted share unit liabilities, warrant liabilities and Class UA preferred stock that may require future cash outlays.
	Investments
	Investments are classified as available-for-sale securities and are carried at fair value with unrealized temporary holding gains and losses, where applicable, excluded from net income or loss and reported in other comprehensive income or loss and also as a net amount in accumulated other comprehensive income or loss until realized. Available-for-sale securities are written down to fair value through income whenever it is necessary to reflect an other-than-temporary impairment. The Company determined that the unrealized losses on its marketable securities as of September 30, 2014 were temporary in nature, and the Company currently does not intend to sell these securities before recovery of their amortized cost basis. All short-term investments are limited to a final maturity of less than one year from the reporting date. The Company’s long-term investments are investments with maturities exceeding 12 months but less than five years from the reporting date. The Company is exposed to credit risk on its cash equivalents, short-term investments and long-term investments in the event of non-performance by counterparties, but does not anticipate such non-performance and mitigates exposure to concentration of credit risk through the nature of its portfolio holdings. If a security falls out of compliance with the Company’s investment policy, it may be necessary to sell the security before its maturity date in order to bring the investment portfolio back into compliance. The cost basis of any securities sold is determined by specific identification. The fair value of available-for-sale securities is based on prices obtained from a third-party pricing service. The Company utilizes third-party pricing services for all of its marketable debt security valuations. The Company reviews the pricing methodology used by the third-party pricing services including the manner employed to collect market information. On a periodic basis, the Company also performs review and validation procedures on the pricing information received from the third-party pricing services. These procedures help ensure that the fair value information used by the Company is determined in accordance with applicable accounting guidance. The amortized cost, unrealized gain or losses and fair value of the Company’s cash, cash equivalents and investments for the periods presented are summarized below:
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
		(In thousands)
	As of September 30, 2014
	Cash	$	4,962	$	—	$	—		$	4,962
	Money market funds		29,280		—		—			29,280
	Debt securities of U.S. government agencies		41,925		13		(2	)		41,936
	Corporate bonds		15,062		11		(6	)		15,067
	Total	$	91,229	$	24	$	(8	)	$	91,245
	As of December 31, 2013
	Cash	$	3,221	$	—	$	—		$	3,221
	Money market funds		6,058		—		—			6,058
	Debt securities of U.S. government agencies		49,878		18		(6	)		49,890
	Corporate bonds		13,390		4		(1	)		13,393
	Total	$	72,547	$	22	$	(7	)	$	72,562
	The following table summarizes the Company’s available-for-sale securities by contractual maturity:
		As of September 30, 2014				As of December 31, 2013
		Amortized Cost		Fair Value		Amortized Cost			Fair Value
		(In thousands)
	Less than one year	$	75,783	$	75,800	$	56,789		$	56,806
	Greater than one year but less than five years		10,484		10,483		12,537			12,535
	Total	$	86,267	$	86,283	$	69,326		$	69,341
	Accounts and Other Receivables, Accounts Payable and Accrued and Other Liabilities
	The carrying amounts of accounts and other receivables, accounts payable and accrued and other liabilities approximate their fair values due to the short-term nature of these financial instruments.
	Class UA Preferred Stock
	The fair value of class UA preferred stock is assumed to be equal to its carrying value as the amounts that will be paid and the timing of the payments cannot be determined with any certainty.
	Limitations
	Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of significant judgment; therefore, they cannot be determined with precision. Changes in assumptions could significantly affect the estimates.

Note_6_Net_Loss_Per_Share

Note 6 - Net Loss Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	6.     NET LOSS PER SHARE
	Basic net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding for the period. Diluted net loss per share is calculated by adjusting the numerator and denominator of the basic net loss per share calculation for the effects of all potentially dilutive common shares. Potential dilutive shares of the Company’s common stock include stock options, restricted share units, warrants, Series A convertible preferred stock and shares granted under the 2010 Employee Stock Purchase Plan (ESPP). The calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of such securities are dilutive to loss per share for the period, adjustments to net loss used in the calculation are required to remove the change in fair value of the warrants for the period. Furthermore, adjustments to the denominator are required to reflect the addition of the related dilutive shares.
	The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share for the three and nine months ended September 30, 2014 and September 30, 2013:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
		(in thousands, except share and per share amounts)
	Numerator
	Net loss used to compute net loss per share:
	Basic	$	(6,736	)	$	(7,710	)	$	(22,384	)	$	(32,396	)
	Adjustments for change in fair value of warrant liability		—			—			—			—
	Diluted	$	(6,736	)	$	(7,710	)	$	(22,384	)	$	(32,396	)
	Denominator
	Weighted average shares outstanding used to compute net loss per share:
	Basic		77,237,246			63,886,874			72,919,829			59,962,328
	Dilutive effect of warrants		—			—			—			—
	Diluted		77,237,246			63,886,874			72,919,829			59,962,328
	Net loss per share—basic and diluted	$	(0.09	)	$	(0.12	)	$	(0.31	)	$	(0.54	)
	The following table presents the number of shares that were excluded from the number of shares used to calculate diluted net loss per share:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Director and employee stock options		4,050,033			2,909,699			4,050,033			2,909,699
	Warrants		8,230,848			10,922,090			8,230,848			10,922,090
	Series A convertible preferred stock (as converted to common stock)		10,000,000			—			10,000,000			—
	Non-employee director restricted share units		163,204			215,829			163,204			215,829
	Employee stock purchase plan		23,780			23,374			23,780			23,374

Note_7_Acquisition

Note 7 - Acquisition	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Business Combination Disclosure [Text Block]	'
	7.     ACQUISITION
	On August 8, 2014, the Company entered into an Agreement and Plan of Reorganization (Merger Agreement) with Alpine Biosciences, Inc. (Alpine), a privately held biotechnology company developing protocells, a nanoparticle capable of delivery of nucleic acids, proteins, peptides and small molecules. Pursuant to the terms and conditions set forth in the Merger Agreement, on August 8, 2014, the Company, through a wholly-owned subsidiary of the Company, consummated the acquisition of Alpine. The merger consideration received by Alpine stockholders was 10% of the Company’s total capital stock determined on a fully-diluted basis immediately following the closing of the merger (Merger Consideration). The total value of the acquisition was approximately $27.2 million based on the closing price of Oncothyreon’s common stock on the day of the merger, which was $2.93 per share. An amount of stock equal to 12.5% of the Merger Consideration was placed in escrow as security for the indemnification obligations of Alpine’s stockholders. The Company intends to utilize the protocell technology to develop new product candidates for the treatment of cancer and rare diseases, either on its own or with partners.
	The transaction has been accounted for using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their estimated fair values as of the acquisition date and that intangible assets with indefinite lives be recorded at fair value on the balance sheet for in-process research and development (IPR&D) activities, regardless of the likelihood of success of the related product or technology. The excess of the aggregate fair value of consideration exchanged for an acquired business over the fair value of assets acquired including tangible assets and indefinite-lived intangible assets and liabilities assumed is recorded as Goodwill. Goodwill represents the anticipated synergies from combining the acquired assets with the Company.
	Recognition and Measurement of Assets Acquired and Liabilities Assumed at Estimated Fair Value
	The total purchase consideration has been allocated to the assets acquired and liabilities assumed, including identifiable intangible assets, based on their respective fair values at the acquisition date. Goodwill was derived from the excess of the aggregate fair value of consideration exchanged for the acquisition of Alpine over the fair value of assets acquired and liabilities assumed. Based upon the fair values determined by the Company, in which the Company considered or relied in part upon a valuation report of a third-party expert. These fair value measurements were based on Level 3 measurements under the fair value hierarchy. The following table summarizes the preliminary allocation of the purchase price for the acquisition pending final adjustments to working capital (in thousands):
	Indefinite-lived intangible assets	$	19,738
	Goodwill		14,542
	Net tangible assets		(139	)
	Deferred tax liabilities		(6,908	)
	Total purchase price allocation	$	27,233
	Goodwill
	The changes in the carrying amount of goodwill for the nine months ended September 30, 2014 were as follows (in thousands):
	Balance as of December 31, 2013	$	2,117
	Goodwill recorded in connection with the acquisition of Alpine		14,542
	Balance as of September 30, 2014	$	16,659
	The goodwill recognized from the acquisition of Alpine is not deductible for tax purposes.
	Intangible Assetswith Indefinite Lives
	Intangible assets with indefinite lives represent the value assigned to IPR&D that, as of the acquisition date, the Company determined that technological feasibility had not been established, and the IPR&D had no alternative future use. IPR&D represents a series of awarded patents and filed patent applications that are the basis of the platform which forms a major part of the planned future products. The indefinite-lived intangible assets will be subject to annual impairment testing until completion or abandonment of the projects. Upon completion of the project, the Company will make a separate determination of useful life of the indefinite-lived intangible assets and the related amortization will be recorded as an expense over the estimated useful life.
	The fair value of the indefinite-lived intangible assets of $19.7 million was determined by the Company, which relied upon a valuation report from an independent third party valuation expert using the income approach and estimates and assumptions provided by the Company’s management. The income approach is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. The rates utilized to discount net cash flows to their present values were based on a range of discount rates of 40% to 60% applied to the intangible assets to reflect the risk of the asset revenues derived from the respective intangible asset. Subsequent to the closing of the merger, research and development cost incurred on the IPR&D and general and administrative expenses associated with salaries and legal costs are expensed as incurred. From August 8, 2014 to September 30, 2014, the Company incurred nominal expenses from Alpine.
	Deferred Tax Liabilities
	Deferred tax liabilities of $6.9 million were the result of book versus tax difference attributable to the identifiable intangible asset multiplied by the statutory tax rate for the relevant jurisdiction.
	Acquisition-Related Expenses
	Acquisition-related expenses of $0.5 million, including legal and regulatory costs, were expensed as incurred and recorded in general and administrative expense in the Company’s condensed consolidated statements of operations for the three and nine months ended September 30, 2014.
	Unaudited Pro Forma Financial Information
	The following pro forma condensed combined financial information gives effect to the acquisition of Alpine as if it were consummated on January 1, 2013 (the beginning of the comparable prior reporting period), and includes pro forma adjustments related to share-based compensation expense and direct and incremental transaction costs reflected in the historical financial statements. The pro forma condensed combined financial information is presented for informational purposes only. The pro forma condensed combined financial information is not intended to represent or be indicative of the results of operations that would have been reported had the acquisition occurred on January 1, 2013 and should not be taken as representative of future results of operations of the combined company.
	The following table presents the unaudited pro forma condensed combined financial information (in thousands, except per share amounts):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
								(Unaudited)
	Net loss	$	(6,800	)	$	(7,832	)	$	(23,722	)	$	(32,717	)
	Net loss per share – basic and diluted	$	(0.08	)	$	(0.11	)	$	(0.30	)	$	(0.47	)

Note_8_Equity

Note 8 - Equity	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	8.     EQUITY
	Amended and Restated Certificate of Incorporation
	On June 6, 2014, the stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of the Company's authorized common shares from 100,000,000 to 200,000,000. On June 6, 2014, the Company filed a Certificate of Amendment with the Delaware Secretary of State to effect such amendment.
	Certificate of Designation
	On September 22, 2014, in connection with the public offering of 10,000 shares of the Company’s Series A convertible preferred stock, the Company designated 10,000 shares of its authorized and unissued preferred stock as Series A convertible preferred stock and filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock with the Delaware Secretary of State. Each share of Series A convertible preferred stock is convertible into 1,000 shares of the Company’s common stock at any time at the holder’s option. The holder, however, will be prohibited from converting Series A convertible preferred stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of the Company’s common stock then issued and outstanding. In the event of the Company’s liquidation, dissolution, or winding up, holders of Series A convertible preferred stock will receive a payment equal to $0.0001 per share of Series A convertible preferred stock before any proceeds are distributed to the holders of common stock, but after any proceeds are distributed to the holder of the Company’s Class UA preferred stock. Shares of Series A convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of holders of a majority of the outstanding Series A convertible preferred stock will be required to amend the terms of the Series A convertible preferred stock. Shares of Series A convertible preferred stock will not be entitled to receive any dividends, unless and until specifically declared by the Company’s board of directors, and will rank:
		●	senior to all common stock;
		●	senior to any class or series of capital stock hereafter created specifically ranking by its terms junior to the Series A convertible preferred stock;
		●	on parity with any class or series of capital stock hereafter created specifically ranking by its terms on parity with the Series A convertible preferred stock; and
		●	junior to the Company’s Class UA preferred stock and any class or series of capital stock hereafter created specifically ranking by its terms senior to the Series A convertible preferred stock;
	in each case, as to distribution of assets upon the Company’s liquidation, dissolution or winding up whether voluntarily or involuntarily.
	“At-the-Market” Equity Offering Program
	On February 3, 2012, the Company entered into a Sales Agreement (the Sales Agreement) with Cowen and Company, LLC (Cowen) to sell shares of the Company’s common stock, having aggregate gross sales proceeds up to $50,000,000, from time to time, through an “at-the-market” equity offering program under which Cowen acted as sales agent. Under the Sales Agreement, the Company set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The Sales Agreement provided that Cowen would be entitled to compensation for its services that would not exceed, but could be lower than, 3.0% of the gross sales price per share of all shares sold through Cowen under the Sales Agreement. On July 1, 2013, the Company commenced selling its common stock through the “at the market” equity offering program under the Sales Agreement. On September 17, 2014, the Company terminated the Sales Agreement in connection with the Company’s September 2014 equity offering as described in the following paragraph. The Company was not subject to any termination penalties related to termination of the Sales Agreement. As of September 17, 2014, the Company had sold an aggregate of 8,364,379 shares of its common stock under the Sales Agreement for gross proceeds of $16.6 million. The net proceeds from the sale of the shares, after deducting commission of approximately $0.5 million, were approximately $16.1 million.
	Equity Financing
	On September 18, 2014, the Company entered into two underwriting agreements (each, an Underwriting Agreement) with Cowen as representative of the underwriters named therein (Underwriters) for concurrent but separate offerings of the Company’s securities. On September 23, 2014, the Company closed concurrent but separate underwritten offerings of 10,000,000 shares of its common stock at a price of $2.00 per share, for gross proceeds of $20 million, and 10,000 shares of its Series A convertible preferred stock at a price of $2,000 per share, for gross proceeds of $20 million. Each share of Series A convertible preferred stock is non-voting and convertible into 1,000 shares of the Company’s common stock at any time at the option of the holder, provided that conversion will be prohibited if, as a result, the holder and its affiliates would beneficially own more than 4.99% of the common stock then outstanding. As part of the common stock offering, the Company also granted the underwriters, and the underwriters exercised, a 30-day option to purchase 1,500,000 additional shares of the Company’s common stock. Aggregate gross proceeds from the offerings was approximately $43.0 million. Aggregate net proceeds from the offerings, after commissions and estimated expenses of $2.8 million, was approximately $40.2 million which included $21.6 million from the Company’s common stock offering and $18.6 million from the Company’s Series A convertible preferred stock offering.
	On June 4, 2013, the Company closed a registered direct offering of 5,000,000 units, with each unit consisting of one share of the Company’s common stock and a warrant to purchase one share of the Company’s common stock, at $2.00 per unit for gross proceeds of $10 million. The warrants are exercisable at an exercise price of $5.00 per share any time on or after December 5, 2013 and expire December 5, 2018. The shares and warrants were sold to Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. in a registered direct offering conducted without an underwriter or placement agent. The net proceeds from the offering, after deducting estimated offering expenses, were approximately $9.9 million.

Note_9_Warrants

Note 9 - Warrants	9 Months Ended
	Sep. 30, 2014
Warrants and Rights Note Disclosure [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	9.     WARRANTS
	Warrants consist of liability-classified warrants and equity-classified warrants. As of September 30, 2014, warrants to purchase a total of 8,230,848 shares of the Company’s common stock were outstanding.  During the nine months ended September 30, 2014, liability-classified warrants to purchase 2,691,242 shares of the Company’s common stock expired and no warrants were exercised. During the three months ended September 30, 2014 and the three and nine months ended September 30, 2013, no warrants were exercised or expired.
	Equity-Classified Warrants
	Equity-classified warrants consist of warrants issued in connection with the Company’s registered direct offering to Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. (collectively, BVF) and warrants issued in connection with a term loan with General Electric Capital Corporation (GECC). In June 2013, the Company issued warrants to purchase 5,000,000 shares of common stock at an exercise price of $5.00 per share in connection with a registered direct offering to BVF. The warrants expire on December 5, 2018. In February 2011, the Company issued warrants to purchase 48,701 shares of common stock at an exercise price of $3.08 per share in connection with a loan and security agreement entered into with GECC. The warrants expire on February 8, 2018. As of September 30, 2014, warrants to purchase 5,048,701 shares of common stock were outstanding and classified as equity.
	Liability-Classified Warrants
	Liability-classified warrants consist of warrants issued in conjunction with an equity financing in September 2010. The warrants issued in September 2010 have been classified as liabilities, as opposed to equity, due to potential cash settlements upon the occurrence of certain transactions specified in the warrant agreement. As of September 30, 2014, warrants to purchase 3,182,147 shares of the Company’s common stock from the September 2010 financing that expire on October 12, 2015 were outstanding and classified as a liability. Warrants to purchase 2,691,242 shares of the Company’s common stock from a May 2009 financing expired on May 26, 2014.
	The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. The change in the estimated fair value of such warrants is recorded in the condensed consolidated statement of operations as other income (expenses). The fair value of the warrants is estimated using the Black-Scholes option-pricing model with the following inputs for the warrants:
		As of September 30, 2014
		Sep-10
		Warrants
	Exercise price	$	4.24
	Market value of stock at end of period	$	1.92
	Expected dividend rate		0	%
	Expected volatility		68.3	%
	Risk-free interest rate		0.1	%
	Expected life (in years)		1.03
		As of December 31, 2013
		May-09			Sep-10
		Warrants			Warrants
	Exercise price	$	3.74		$	4.24
	Market value of stock at end of period	$	1.76		$	1.76
	Expected dividend rate		0	%		0	%
	Expected volatility		45.3	%		77.4	%
	Risk-free interest rate		0.1	%		0.3	%
	Expected life (in years)		0.4			1.78
	The fair value of the warrant liability and the changes in its fair value during the three and nine months ended September 30, 2014 and September 30, 2013 were as follows:
		Three months ended September 30,
		2014			2013
		(In thousands)
	Balance at beginning of period	$	1,656		$	1,951
	Change in fair value of warrant liability included in:
	Other expense (income)		(1,273	)		174
	Balance at the end of period	$	383		$	2,125
		Nine months ended September 30,
		2014			2013
		(In thousands)
	Balance at beginning of period	$	924		$	3,251
	Change in fair value of warrant liability included in:
	Other expense (income)		(541	)		(1,126	)
	Balance at the end of period	$	383		$	2,125
	Expected volatility is an unobservable input that is inter-related with the market value or price of the Company’s stock, since the calculation of volatility is based on the Company’s historical closing prices. If volatility were to increase or decrease by 10%, the value of the warrant liability would increase or decrease respectively, by approximately $0.1 million.

Note_10_Sharebased_Compensatio

Note 10 - Share-based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	10.     SHARE-BASED COMPENSATION
	Share Option Plan
	The Company sponsors an option plan (the Share Option Plan) under which a maximum fixed reloading percentage of 10% of the issued and outstanding common stock of the Company may be granted to employees, directors and service providers. Options granted under the Share Option Plan prior to January 2010 began vesting after one year from the date of grant, are exercisable in equal amounts over four years on the anniversary date of the grant, and expire eight years following the date of grant. Options granted under the Share Option Plan after January 2010 vest 25% on the first anniversary of the vesting commencement date, with the balance vesting in monthly increments for 36 months following the first anniversary of hiring, and expire eight years following the date of grant. As of September 30, 2014, the number of shares of common stock reserved for issuance under the Share Option Plan was 9,155,597. As of September 30, 2014, 2,998,360 shares of common stock remained available for future grant under the Share Option Plan.
	During the three months ended September 30, 2014 and September 30, 2013, the Company granted 104,000 and 10,000 stock options, respectively. Stock compensation expense was $0.4 million in each of the three months ended September 30, 2014 and September 30, 2013. During the nine months ended September 30, 2014 and September 30, 2013, the Company granted 185,500 and 10,000 stock options, respectively. Stock compensation expense was $1.3 million in each of the nine months ended September 30, 2014 and September 30, 2013. The number of stock options granted during the three and nine months ended September 30, 2014 was higher primarily due to the stock options issued as new hire grants in conjunction with the acquisition of Alpine during the period. Zero and 1,000 stock options were exercised during the three and nine months ended September 30, 2014, respectively. No stock options were exercised during the three and nine months ended September 30, 2013.
	The Company uses the Black-Scholes option pricing model to value the options at each grant date, using the following weighted average assumptions:
		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014			2013
	Weighted average grant-date fair value for stock options granted	$	1.58		$	1.27		$	1.5		$	1.27
	Expected dividend rate		0	%		0	%		0	%		0	%
	Expected volatility		82.02	%		89.64	%		75.1	%		89.64	%
	Risk-free interest rate		1.91	%		1.8	%		1.42	%		1.8	%
	Expected life of options (in years)		6			6			4.59			6
	The expected life represents the period that the Company’s stock options are expected to be outstanding and was determined based on the simplified method, which calculates the expected life as the average of the vesting term and the contractual term of the option. The Company’s historical stock option exercise data was impacted by a restructuring of its business in 2008. Because the Company does not have sufficient historical stock option exercise data to accurately estimate the expected term used for its valuation of stock options, the Company continues to use the simplified method to calculate the expected term of new stock option grants to employees. As the Company accumulates more data and history related to the exercises of stock option awards, the Company will reassess its use of the simplified method to determine the expected term. The expected volatility is based on the historical volatility of the Company’s common stock for a period equal to the stock option’s expected life. The risk-free interest rate is based on the yield at the time of grant of a U.S. Treasury security with an equivalent expected term of the option. The Company does not expect to pay dividends on its common stock. The amounts estimated according to the Black-Scholes option pricing model may not be indicative of the actual values realized upon the exercise of these options by the holders.
	Share-based compensation guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. The Company estimates forfeitures based on its historical experience.
	Employee Stock Purchase Plan
	The Company adopted an Employee Stock Purchase Plan (ESPP) on June 3, 2010, pursuant to which a total of 900,000 shares of common stock were reserved for sale to employees of the Company. The ESPP is administered by the compensation committee of the board of directors and is open to all eligible employees of the Company. Under the terms of the ESPP, eligible employees may purchase shares of the Company’s common stock at six month intervals during 18-month offering periods through periodic payroll deductions, which may not exceed 15% of any employee’s compensation and may not exceed a value of $25,000 in any calendar year, at a price not less than the lesser of an amount equal to 85% of the fair market value of the Company’s common stock at the beginning of the offering period or an amount equal to 85% of the fair market value of the Company’s common stock on each purchase date. The maximum aggregate number of shares that may be purchased by each eligible employee during each offering period is 15,000 shares of the Company’s common stock. For the three and nine months ended September 30, 2014, expense related to this plan was $19,103 and $83,633, respectively. For the three and nine months ended September 30, 2013, expense related to this plan was $44,273 and $107,847, respectively. Under the ESPP, the Company did not issue any shares to employees during each of the three month periods ended September 30, 2014 and September 30, 2013. The Company issued 36,434 shares and 35,895 shares to employees during the nine months ended September 30, 2014 and September 30, 2013, respectively. There are 640,910 shares reserved for future issuances under the ESPP as of September 30, 2014.
	Restricted Share Unit Plan
	The Company also sponsors a restricted share unit plan (RSU Plan) for non-employee directors that was established in 2005. The RSU Plan provides for grants to be made from time to time by the board of directors or a committee thereof. Each restricted stock unit granted will be made in accordance with the RSU Plan and terms specific to that grant and will be converted into one share of common stock less the cash payment provisions described below at the end of the grant period (not to exceed five years) without any further consideration payable to the Company in respect thereof. On June 6, 2014, the Company’s stockholders approved an increase of 500,000 shares in the number of shares of the Company’s common stock reserved for issuance under the RSU Plan. The current maximum number of common shares of the Company reserved for issuance pursuant to the RSU Plan is 966,666. As of September 30, 2014, 530,910 shares of common stock remain available for future grant under the RSU Plan. The Company did not grant any RSUs during the three months ended September 30, 2014 and September 30, 2013. The Company granted 81,695 restricted share units (RSUs) with a fair value of $250,000 during the nine months ended September 30, 2014 and 80,210 RSUs with a fair value of $150,000 during the nine months ended September 30, 2013. No shares were issued upon conversion of RSUs for the three months ended September 30, 2014 and September 30, 2013. 110,104 shares and 22,690 shares were issued upon conversion of RSUs for the nine months ended September 30, 2014 and September 30, 2013, respectively. The fair value of each RSU has been determined to be the closing trading price of the Company’s common shares on the date of grant as quoted in NASDAQ Global Market.
	Approximately 25% of each RSU represents a contingent right to receive cash upon vesting, and the Company is required to deliver an amount in cash equal to the fair market value of such shares on the vesting date to facilitate the satisfaction of the non-employee directors’ U.S. federal income tax obligation with respect to the vested RSUs. The outstanding RSU awards are required to be remeasured at each reporting date until settlement of the award, and changes in valuation are recorded as compensation expense for the period. To the extent that the liability recorded in the balance sheet is less than the original award value, the difference is recognized in equity. The fair value of the outstanding RSUs on the reporting date is determined to be the closing trading price of the Company’s common shares on that date.
	The remeasurement of the outstanding RSUs together with the grant and conversion of the RSUs resulted in a reduction of $0.2 million and an additional $0.4 million in share-based compensation expense recorded in general and administrative expenses in the condensed consolidated statement of operations for the three and nine months ended September 30, 2014, respectively. The remeasurement of the outstanding RSUs together with the grant and conversion of the RSUs resulted in an additional $0.1 million and $0.2 million in share-based compensation expense recorded in general and administrative expenses in the condensed consolidated statement of operations for the three and nine months ended September 30, 2013, respectively.

Note_11_Contingencies_Commitme

Note 11 - Contingencies, Commitments, and Guarantees	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Commitments Contingencies and Guarantees [Text Block]	'
	11.     CONTINGENCIES, COMMITMENTS, AND GUARANTEES
	Pursuant to various license agreements, the Company is obligated to make payments based both on the achievement of certain milestones and a percentage of revenues derived from the licensed technology and royalties on net sales.
	In the normal course of operations, the Company indemnifies counterparties in transactions such as purchase and sale contracts for assets or shares, service agreements, director/officer contracts and leasing transactions. These indemnification agreements may require the Company to compensate the counterparties for costs incurred as a result of various events, including environmental liabilities, changes in (or in the interpretation of) laws and regulations, or as a result of litigation claims or statutory sanctions that may be suffered by the counterparties as a consequence of the transaction. The terms of these indemnification agreements vary based upon the contract, the nature of which prevents the Company from making a reasonable estimate of the maximum potential amount that could be required to pay to counterparties. Historically, the Company has not made any significant payments under such indemnification agreements and no amounts have been accrued in the accompanying condensed consolidated financial statements with respect to these indemnification guarantees.

Note_12_Collaborative_and_Lice

Note 12 - Collaborative and License Agreements	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Collaborative Arrangement Disclosure [Text Block]	'
	12.     COLLABORATIVE AND LICENSE AGREEMENTS
	Array BioPharma Inc.
	On May 30, 2013, the Company entered into a collaborative agreement with Array BioPharma Inc. (Array). Under the agreement, Array and the Company will collaborate to develop and commercialize, an orally active, reversible and selective small-molecule HER2 inhibitor which the Company refers to as ONT-380. HER2, also known as ErbB2, is a receptor tyrosine kinase that is over-expressed in breast cancer and other cancers such as gastric and ovarian cancer. Array previously completed a Phase 1 clinical trial of ONT-380 in patients with heavily pre-treated metastatic breast cancer which demonstrated that the compound was well tolerated and had anti-tumor activity.
	In June 2013, the Company paid Array an upfront fee of $10 million, which was recorded as part of research and development expense upon initiation of the collaboration. Under the agreement, the Company will fund and conduct the clinical development of ONT-380 through an agreed, defined set of combination proof-of-concept trials in patients with metastatic breast cancer, including patients with brain metastases.
	The Company and Array intend to jointly conduct Phase 3 development supported by the proof-of-concept studies, with each party retaining the right to opt out of further development and commercialization in exchange for a significant royalty. Array is responsible for worldwide commercialization of the product. The Company has a co-promotion right in the United States and the two companies will share the cost of U.S. commercialization, including any profit, equally. Outside of the United States, the Company will receive a double-digit royalty on net sales intended to approximate a fifty percent profit share, and the two companies will share equally the proceeds from any sublicense of marketing rights.
	Celldex Therapeutics, Inc.
	On May 28, 2014, the Company entered into a Co-Development Agreement with Celldex Therapeutics, Inc. (Celldex) to collaborate on a combined Phase 1b clinical trial of ONT-10 and varlilumab. The primary objective of the trial is to determine the safety and tolerability of the combined therapy. Additional objectives include evaluations of the impact of combination treatment on MUC1-specific humoral and cellular immune responses and anti-tumor effects.
	The agreement provides that the Company will supply ONT-10 and Celldex will supply varlilumab. The Phase 1b trial will be conducted and funded by the Company. The Company and Celldex will jointly own the data from the trial and will make any plans for potential future development of the combination therapy together.
	STC.UNM
	Effective June 30, 2014, Alpine entered into an exclusive license agreement with STC.UNM, by assignment from The Regents of the University of New Mexico, to license the rights to use certain technology relating to protocells and mesoporous silica nanoparticle delivery platform. Under the terms of the license agreement, the Company, as successor to Alpine, has the right to conduct research, clinical development and commercialize all inventions and products that are developed from the platform technology in certain fields of use as described in the license agreement. In exchange for the exclusive license, the Company is obligated to make a series of payments including on-going annual license payments, reimbursement of patent costs, success based milestones, and royalty payments based on net sales, if any. In addition, Alpine issued STC.UNM a number of shares of common stock such that STC.UNM owned 5% of the outstanding equity of Alpine prior to the merger between the Company and Alpine. As of September 30, 2014, the total liabilities under this agreement were approximately $97,000 and related to patent costs. Please refer to “Note 7 - Acquisition” of the unaudited financial statements included in this report for additional information regarding the Company’s acquisition of Alpine.
	Merck KGaA
	The Company has granted an exclusive, worldwide license to Merck KGaA for the development, manufacture and commercialization of tecemotide (formerly known as L-BLP25 or Stimuvax) , a therapeutic vaccine targeting MUC1. The Company has no continuing involvement in the ongoing development, manufacturing or commercialization of tecemotide. In September 2014, Merck KGaA announced that its biopharmaceutical division Merck Serono will discontinue the clinical development program of tecemotide as a monotherapy in Stage III non-small cell lung cancer (NSCLC). As a result, the Company does not anticipate future payments under this license agreement. No amounts were recognized in connection with this agreement during the three and nine months ended September 30, 2014 and September 30, 2013.

Note_13_Income_Tax

Note 13 - Income Tax	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	13.     INCOME TAX
	Due to projected and actual losses for the years ended December 31, 2014 and 2013, respectively, and the Company’s history of losses, the Company has not recorded an income tax benefit for the three and nine months ended September 30, 2014 and September 30, 2013. The Company has recognized a full valuation allowance on its deferred tax assets. The Company’s net deferred tax assets and net deferred tax liabilities were recorded in other assets and accrued and other liabilities, respectively on the Condensed Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013.  Additional deferred tax liabilities, which related to indefinite lived intangible assets acquired in the nontaxable acquisition of Alpine on August 8, 2014, were recorded to long term deferred tax liability on the Condensed Consolidated Balance Sheets as of September 30, 2014. Because the reversal periods of deferred tax liabilities related to indefinite lived intangibles is not certain, these deferred tax liabilities are not considered a source of income for valuation allowance determination.  Therefore, there was no change to the preexisting valuation allowance as a result of the acquisition, and a net deferred tax liability in the amount of $6.9 million was recorded during the quarter through an adjustment to goodwill. The estimated annual effective tax rate used in the quarter was zero and the Alpine acquisition is not expected to have a material effect on the Company’s forecasted tax rate due to expected losses.

Note_14_Subsequent_Events

Note 14 - Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	14.     SUBSEQUENT EVENTS
	None

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial statements. The accounting principles and methods of computation adopted in these condensed consolidated financial statements are the same as those of the audited consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities Exchange Commission (the SEC) on March 13, 2014.
	Omitted from these statements are certain information and note disclosures normally included in the audited consolidated financial statements prepared in accordance with U.S. GAAP. The Company believes all adjustments necessary for a fair statement of the results for the periods presented have been made, and such adjustments consist only of those considered normal and recurring in nature. The financial results for the three and nine months ended September 30, 2014 are not necessarily indicative of financial results for the full year. The condensed consolidated balance sheet as of December 31, 2013 has been derived from the audited financial statements at that date. The unaudited condensed consolidated financial statements and notes presented should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 13, 2014.
Comprehensive Income, Policy [Policy Text Block]	'
	Accumulated Other Comprehensive Income (Loss)
	Comprehensive income or loss is comprised of net income or loss and other comprehensive income or loss. Other comprehensive income or loss includes unrealized gains and losses on the Company’s available-for-sale investments. In addition to unrealized gains and losses on investments, accumulated other comprehensive income or loss consists of foreign currency translation adjustments which arose from the conversion of the Canadian dollar functional currency consolidated financial statements to the U.S. dollar reporting currency consolidated financial statements prior to January 1, 2008. Should the Company liquidate or substantially liquidate its investments in its foreign subsidiaries, the Company would be required to recognize the related cumulative translation adjustments pertaining to the liquidated or substantially liquidated subsidiaries, as a charge to earnings in the Company’s condensed consolidated statements of operations and comprehensive loss.
	There were no reclassifications out of accumulated other comprehensive loss during the three and nine months ended September 30, 2014. The tables below show the changes in accumulated balances of each component of accumulated other comprehensive loss for the three and nine months ended September 30, 2014 and September 30, 2013:
		Three months ended September 30, 2014
		Net unrealized gains/(losses) on Available-for-sale Securities			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Loss
		(In thousands)
	Balance at July 1, 2014	$	17		$	(5,066	)	$	(5,049	)
	Current period other comprehensive loss		(1	)		—			(1	)
	Balance at September 30, 2014	$	16		$	(5,066	)	$	(5,050	)
		Nine months ended September 30, 2014
		Net unrealized gains/(losses) on Available-for-sale Securities			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Loss
		(In thousands)
	Balance at December 31, 2013	$	15		$	(5,066	)	$	(5,051	)
	Current period other comprehensive income		1			—			1
	Balance at September 30, 2014	$	16		$	(5,066	)	$	(5,050	)
		Three months ended September 30, 2013
		Net unrealized gains/(losses) on Available-for-sale Securities			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Loss
		(In thousands)
	Balance at July 1, 2013	$	9		$	(5,066	)	$	(5,057	)
	Current period other comprehensive income		22			—			22
	Balance at September 30, 2013	$	31		$	(5,066	)	$	(5,035	)
		Nine months ended September 30, 2013
		Net unrealized gains/(losses) on Available-for-sale Securities			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Loss
		(In thousands)
	Balance at December 31, 2012	$	30		$	(5,066	)	$	(5,036	)
	Current period other comprehensive income		1			—			1
	Balance at September 30, 2013	$	31		$	(5,066	)	$	(5,035	)

Note_2_Basis_of_Presentation_T

Note 2 - Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
		Three months ended September 30, 2014
		Net unrealized gains/(losses) on Available-for-sale Securities			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Loss
		(In thousands)
	Balance at July 1, 2014	$	17		$	(5,066	)	$	(5,049	)
	Current period other comprehensive loss		(1	)		—			(1	)
	Balance at September 30, 2014	$	16		$	(5,066	)	$	(5,050	)
		Nine months ended September 30, 2014
		Net unrealized gains/(losses) on Available-for-sale Securities			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Loss
		(In thousands)
	Balance at December 31, 2013	$	15		$	(5,066	)	$	(5,051	)
	Current period other comprehensive income		1			—			1
	Balance at September 30, 2014	$	16		$	(5,066	)	$	(5,050	)
		Three months ended September 30, 2013
		Net unrealized gains/(losses) on Available-for-sale Securities			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Loss
		(In thousands)
	Balance at July 1, 2013	$	9		$	(5,066	)	$	(5,057	)
	Current period other comprehensive income		22			—			22
	Balance at September 30, 2013	$	31		$	(5,066	)	$	(5,035	)
		Nine months ended September 30, 2013
		Net unrealized gains/(losses) on Available-for-sale Securities			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Loss
		(In thousands)
	Balance at December 31, 2012	$	30		$	(5,066	)	$	(5,036	)
	Current period other comprehensive income		1			—			1
	Balance at September 30, 2013	$	31		$	(5,066	)	$	(5,035	)

Note_4_Fair_Value_Measurements1

Note 4 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
		30-Sep-14								31-Dec-13
		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
		(In thousands)
	Financial assets:
	Money market funds	$	29,280	$	—	$	—	$	29,280	$	6,058	$	—	$	—	$	6,058
	Debt securities of U.S. government agencies		—		41,936		—		41,936		—		49,890		—		49,890
	Corporate bonds		—		15,067		—		15,067		—		13,393		—		13,393
		$	29,280	$	57,003	$	—	$	86,283	$	6,058	$	63,283	$	—	$	69,341
	Financial liabilities:
	Restricted share units	$	313	$	—	$	—	$	313	$	337	$	—	$	—	$	337
	Warrants	$	—	$	—	$	383	$	383	$	—	$	—	$	924	$	924

Note_5_Financial_Instruments_T

Note 5 - Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Unrealized Gain (Loss) on Investments [Table Text Block]	'
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
		(In thousands)
	As of September 30, 2014
	Cash	$	4,962	$	—	$	—		$	4,962
	Money market funds		29,280		—		—			29,280
	Debt securities of U.S. government agencies		41,925		13		(2	)		41,936
	Corporate bonds		15,062		11		(6	)		15,067
	Total	$	91,229	$	24	$	(8	)	$	91,245
	As of December 31, 2013
	Cash	$	3,221	$	—	$	—		$	3,221
	Money market funds		6,058		—		—			6,058
	Debt securities of U.S. government agencies		49,878		18		(6	)		49,890
	Corporate bonds		13,390		4		(1	)		13,393
	Total	$	72,547	$	22	$	(7	)	$	72,562
Investments Classified by Contractual Maturity Date [Table Text Block]	'
		As of September 30, 2014				As of December 31, 2013
		Amortized Cost		Fair Value		Amortized Cost			Fair Value
		(In thousands)
	Less than one year	$	75,783	$	75,800	$	56,789		$	56,806
	Greater than one year but less than five years		10,484		10,483		12,537			12,535
	Total	$	86,267	$	86,283	$	69,326		$	69,341

Note_6_Net_Loss_Per_Share_Tabl

Note 6 - Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
		(in thousands, except share and per share amounts)
	Numerator
	Net loss used to compute net loss per share:
	Basic	$	(6,736	)	$	(7,710	)	$	(22,384	)	$	(32,396	)
	Adjustments for change in fair value of warrant liability		—			—			—			—
	Diluted	$	(6,736	)	$	(7,710	)	$	(22,384	)	$	(32,396	)
	Denominator
	Weighted average shares outstanding used to compute net loss per share:
	Basic		77,237,246			63,886,874			72,919,829			59,962,328
	Dilutive effect of warrants		—			—			—			—
	Diluted		77,237,246			63,886,874			72,919,829			59,962,328
	Net loss per share—basic and diluted	$	(0.09	)	$	(0.12	)	$	(0.31	)	$	(0.54	)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
	Director and employee stock options		4,050,033			2,909,699			4,050,033			2,909,699
	Warrants		8,230,848			10,922,090			8,230,848			10,922,090
	Series A convertible preferred stock (as converted to common stock)		10,000,000			—			10,000,000			—
	Non-employee director restricted share units		163,204			215,829			163,204			215,829
	Employee stock purchase plan		23,780			23,374			23,780			23,374

Note_7_Acquisition_Tables

Note 7 - Acquisition (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'
	Indefinite-lived intangible assets	$	19,738
	Goodwill		14,542
	Net tangible assets		(139	)
	Deferred tax liabilities		(6,908	)
	Total purchase price allocation	$	27,233
Schedule of Goodwill [Table Text Block]	'
	Balance as of December 31, 2013	$	2,117
	Goodwill recorded in connection with the acquisition of Alpine		14,542
	Balance as of September 30, 2014	$	16,659
Business Acquisition, Pro Forma Information [Table Text Block]	'
		Three Months Ended September 30,						Nine Months Ended September 30,
		2014			2013			2014			2013
								(Unaudited)
	Net loss	$	(6,800	)	$	(7,832	)	$	(23,722	)	$	(32,717	)
	Net loss per share – basic and diluted	$	(0.08	)	$	(0.11	)	$	(0.30	)	$	(0.47	)

Note_9_Warrants_Tables

Note 9 - Warrants (Tables)	9 Months Ended
	Sep. 30, 2014
Warrants and Rights Note Disclosure [Abstract]	'
Schedule Of Warrants Valuation Assumptions Table Text Block	'
		As of September 30, 2014
		Sep-10
		Warrants
	Exercise price	$	4.24
	Market value of stock at end of period	$	1.92
	Expected dividend rate		0	%
	Expected volatility		68.3	%
	Risk-free interest rate		0.1	%
	Expected life (in years)		1.03
		As of December 31, 2013
		May-09			Sep-10
		Warrants			Warrants
	Exercise price	$	3.74		$	4.24
	Market value of stock at end of period	$	1.76		$	1.76
	Expected dividend rate		0	%		0	%
	Expected volatility		45.3	%		77.4	%
	Risk-free interest rate		0.1	%		0.3	%
	Expected life (in years)		0.4			1.78
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
		Three months ended September 30,
		2014			2013
		(In thousands)
	Balance at beginning of period	$	1,656		$	1,951
	Change in fair value of warrant liability included in:
	Other expense (income)		(1,273	)		174
	Balance at the end of period	$	383		$	2,125
		Nine months ended September 30,
		2014			2013
		(In thousands)
	Balance at beginning of period	$	924		$	3,251
	Change in fair value of warrant liability included in:
	Other expense (income)		(541	)		(1,126	)
	Balance at the end of period	$	383		$	2,125

Note_10_Sharebased_Compensatio1

Note 10 - Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014			2013
	Weighted average grant-date fair value for stock options granted	$	1.58		$	1.27		$	1.5		$	1.27
	Expected dividend rate		0	%		0	%		0	%		0	%
	Expected volatility		82.02	%		89.64	%		75.1	%		89.64	%
	Risk-free interest rate		1.91	%		1.8	%		1.42	%		1.8	%
	Expected life of options (in years)		6			6			4.59			6

Note_2_Basis_of_Presentation_D

Note 2 - Basis of Presentation (Details) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Disclosure Text Block [Abstract]	'	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	$0	$0

Note_2_Basis_of_Presentation_D1

Note 2 - Basis of Presentation (Details) - Changes in Accumulated Other Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Changes in Accumulated Other Comprehensive Loss [Abstract]	'	'	'	'
Beginning Balance of Net unrealized gains/(losses) on Available-for-sale Securities	$17	$9	$15	$30
Beginning Balance of Foreign Currency Translation Adjustment	-5,066	-5,066	-5,066	-5,066
Beginning Balance of Accumulated Other Comprehensive Loss	-5,049	-5,057	-5,051	-5,036
Change in Net unrealized gains/(losses) on Available-for-sale Securities	-1	22	1	1
Change in Foreign Currency Translation Adjustment	'	0	0	'
Change in Accumulated Other Comprehensive Loss	-1	22	1	1
Ending Balance of Net unrealized gains/(losses) on Available-for-sale Securities	16	31	16	31
Ending Balance of Foreign Currency Translation Adjustment	-5,066	-5,066	-5,066	-5,066
Ending Balance of Accumulated Other Comprehensive Loss	($5,050)	($5,035)	($5,050)	($5,035)

Note_4_Fair_Value_Measurements2

Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	$86,283	$69,341
Restricted Share Units [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Liabilities	313	337
Restricted Share Units [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Liabilities	313	337
Warrants [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Liabilities	383	924
Warrants [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Liabilities	383	924
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	29,280	6,058
Fair Value, Inputs, Level 1 [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	29,280	6,058
Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	41,936	49,890
Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	15,067	13,393
Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	57,003	63,283
Money Market Funds [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	29,280	6,058
US Government Agencies Debt Securities [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	41,936	49,890
Corporate Debt Securities [Member]	'	'
Note 4 - Fair Value Measurements (Details) - Financial Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Financial Assets	$15,067	$13,393

Note_5_Financial_Instruments_D

Note 5 - Financial Instruments (Details) - Amortized Cost, Unrealized Gains or Losses, and Estimated Fair Value of Cash, Cash Equivalents and Investments (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Note 5 - Financial Instruments (Details) - Amortized Cost, Unrealized Gains or Losses, and Estimated Fair Value of Cash, Cash Equivalents and Investments [Line Items]	'	'
Cash, Amortized Cost	$4,962	$3,221
Cash, Fair Value	4,962	3,221
Money Market Funds, Amortized Cost	29,280	6,058
Money Market Funds, Fair Value	29,280	6,058
Debt securities, Amortized Cost	86,267	69,326
Debt securities, Gross Unrealized Gains	24	22
Debt securities, Gross Unrealized Losses	-8	-7
Debt securities, Fair Value	86,283	69,341
Total, Amortized Cost	91,229	72,547
Total, Gross Unrealized Gains	24	22
Total, Gross Unrealized Losses	-8	-7
Total, Fair Value	91,245	72,562
US Government Agencies Debt Securities [Member]	'	'
Note 5 - Financial Instruments (Details) - Amortized Cost, Unrealized Gains or Losses, and Estimated Fair Value of Cash, Cash Equivalents and Investments [Line Items]	'	'
Debt securities, Amortized Cost	41,925	49,878
Debt securities, Gross Unrealized Gains	13	18
Debt securities, Gross Unrealized Losses	-2	-6
Debt securities, Fair Value	41,936	49,890
Total, Gross Unrealized Gains	13	18
Total, Gross Unrealized Losses	-2	-6
Corporate Debt Securities [Member]	'	'
Note 5 - Financial Instruments (Details) - Amortized Cost, Unrealized Gains or Losses, and Estimated Fair Value of Cash, Cash Equivalents and Investments [Line Items]	'	'
Debt securities, Amortized Cost	15,062	13,390
Debt securities, Gross Unrealized Gains	11	4
Debt securities, Gross Unrealized Losses	-6	-1
Debt securities, Fair Value	15,067	13,393
Total, Gross Unrealized Gains	11	4
Total, Gross Unrealized Losses	($6)	($1)

Note_5_Financial_Instruments_D1

Note 5 - Financial Instruments (Details) - Summary of Available-for-Sale Securities by Contractual Maturity (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Summary of Available-for-Sale Securities by Contractual Maturity [Abstract]	'	'
Less than one year	$75,783	$56,789
Less than one year	75,800	56,806
Greater than one year but less than five years	10,484	12,537
Greater than one year but less than five years	10,483	12,535
Total	86,267	69,326
Total	$86,283	$69,341

Note_6_Net_Loss_Per_Share_Deta

Note 6 - Net Loss Per Share (Details) - Reconciliation of the Numerator and Denominator Used in the Caluclation of Basic and Diluted Net Income or Loss Per Share (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator	'	'	'	'
Basic	($6,736)	($7,710)	($22,384)	($32,396)
Diluted	($6,736)	($7,710)	($22,384)	($32,396)
Denominator	'	'	'	'
Basic	77,237,246	63,886,874	72,919,829	59,962,328
Diluted	77,237,246	63,886,874	72,919,829	59,962,328
Net loss per share—basic and diluted	($0.09)	($0.12)	($0.31)	($0.54)

Note_6_Net_Loss_Per_Share_Deta1

Note 6 - Net Loss Per Share (Details) - Number of Shares Excluded from the Number of Shares Used to Calculate Diluted Net Income or Loss Per Share	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Director And Employee Stock Options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Number of shares excluded	4,050,033	2,909,699	4,050,033	2,909,699
Warrant [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Number of shares excluded	8,230,848	10,922,090	8,230,848	10,922,090
Series A Convertible Preferred Stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Number of shares excluded	10,000,000	'	10,000,000	'
Non-Employee Director Restricted Share Units [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Number of shares excluded	163,204	215,829	163,204	215,829
Employee Stock Purchase Plan [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Number of shares excluded	23,780	23,374	23,780	23,374

Note_7_Acquisition_Details

Note 7 - Acquisition (Details) (Alpine Biosciences, Inc. [Member], USD $)	0 Months Ended
	Aug. 08, 2014
Note 7 - Acquisition (Details) [Line Items]	'
Business Acquisition Equity Interest Issued or Issuable Pecentage of Equity	10.00%
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$27,200,000
Business Acquisition, Share Price	$2.93
Percentage Of Acquisition Consideration For Indemnification Obligations	12.50%
Indefinite-lived Intangible Assets Acquired	19,700,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent	6,908,000
Business Combination, Acquisition Related Costs	$500,000
Minimum [Member]	'
Note 7 - Acquisition (Details) [Line Items]	'
Indefinite-Lived Intangible Asset Valuation Discount Rate	40.00%
Maximum [Member]	'
Note 7 - Acquisition (Details) [Line Items]	'
Indefinite-Lived Intangible Asset Valuation Discount Rate	60.00%

Note_7_Acquisition_Details_All

Note 7 - Acquisition (Details) - Allocation of Purchase Price of Assets Acquired and Liabilities Assumed (USD $)	Sep. 30, 2014	Dec. 31, 2013	Aug. 08, 2014
In Thousands, unless otherwise specified			Alpine Biosciences, Inc. [Member]
Note 7 - Acquisition (Details) - Allocation of Purchase Price of Assets Acquired and Liabilities Assumed [Line Items]	'	'	'
Indefinite-lived intangible assets	'	'	$19,738
Goodwill	16,659	2,117	14,542
Net tangible assets	'	'	-139
Deferred tax liabilities	'	'	-6,908
Total purchase price allocation	'	'	$27,233

Note_7_Acquisition_Details_Cha

Note 7 - Acquisition (Details) - Changes in the Carrying Amount of Goodwill. (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Aug. 08, 2014
In Thousands, unless otherwise specified			Alpine Biosciences, Inc. [Member]	Alpine Biosciences, Inc. [Member]
Goodwill [Line Items]	'	'	'	'
Balance as of December 31, 2013	$16,659	$2,117	'	$14,542
Goodwill recorded in connection with the acquisition of Alpine	'	'	14,542	'
Balance as of September 30, 2014	$16,659	$2,117	'	$14,542

Note_7_Acquisition_Details_Una

Note 7 - Acquisition (Details) - Unaudited Pro Forma Financial Information (Alpine Biosciences, Inc. [Member], USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Alpine Biosciences, Inc. [Member]	'	'	'	'
Note 7 - Acquisition (Details) - Unaudited Pro Forma Financial Information [Line Items]	'	'	'	'
Net loss	($6,800)	($7,832)	($23,722)	($32,717)
Net loss per share – basic and diluted	($0.08)	($0.11)	($0.30)	($0.47)

Note_8_Equity_Details

Note 8 - Equity (Details) (USD $)

0 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

Sep. 23, 2014

Jul. 01, 2013

Sep. 17, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 22, 2014

Sep. 18, 2014

Jun. 06, 2014

Jun. 05, 2014

Dec. 31, 2013

Feb. 03, 2012

Sep. 23, 2014

Sep. 22, 2014

Sep. 23, 2014

Sep. 23, 2014

Sep. 23, 2014

Sep. 23, 2014

Feb. 03, 2012

Jun. 04, 2013

Jun. 04, 2013

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Common Stock [Member]

Convertible Preferred Stock [Member]

Additional Shares to Purchase New Shares [Member]

September 2014 Offerings [Member]

Maximum [Member]

Biotechnology Value Fund, L.P. and Other Affiliates of BVF Partners L.P. [Member]

Biotechnology Value Fund, L.P. and Other Affiliates of BVF Partners L.P. [Member]

Cowen and Company, LLC [Member]

Note 8 - Equity (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized (in Shares)

'

'

'

200,000,000

'

'

'

200,000,000

100,000,000

100,000,000

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Issued (in Shares)

'

'

'

10,000

'

'

'

'

'

10,000

'

10,000

10,000

'

'

'

'

'

'

'

Preferred Stock, Permitted to Issue, Shares (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

Convertible Preferred Stock to Be Converted (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

1,000

'

'

'

'

'

'

'

Maximum Ownership Percentage Of Common Shares Outstanding Post Conversion

'

'

'

'

'

'

'

'

'

'

'

'

4.99%

'

'

'

'

'

'

'

Preferred Stock, Liquidation Preference Per Share (in Dollars per share)

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate Gross Sales Proceeds Under Sales Agreement

'

'

'

'

'

'

'

'

'

'

$50,000,000

'

'

'

'

'

'

'

'

'

Sales Agreement Compensation Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

10,000,000

8,364,379

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000

'

'

'

'

Proceeds From Issuance of Common Stock Gross

20,000,000

16,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

Payments of Stock Issuance Costs

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,800,000

'

'

'

Proceeds from Issuance or Sale of Equity

'

'

16,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

40,200,000

'

9,900,000

'

Number Of Underwriting Agreements

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Price Per Share (in Dollars per share)

$2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

$2,000

'

'

'

'

'

'

'

'

Proceeds From Issuance of Convertible Preferred Stock Gross

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

Proceeds From Issuance or Sale of Equity Gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

43,000,000

'

'

'

Proceeds from Issuance of Common Stock

'

'

'

21,622,000

19,686,000

'

'

'

'

'

'

'

'

21,600,000

'

'

'

'

'

'

Proceeds from Issuance of Convertible Preferred Stock

'

'

'

$18,693,000

'

'

'

'

'

'

'

'

'

'

$18,600,000

'

'

'

'

'

Direct Offering, Units Issued (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

Direct Offering, Shares Per Unit Issued (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

Direct Offering Warrants Per Unit Issued (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

Sale Price of Common Stock and Warrants Per Unit (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5

Note_9_Warrants_Details

Note 9 - Warrants (Details) (USD $)	3 Months Ended		9 Months Ended							0 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2013	Feb. 08, 2011	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	26-May-14	Dec. 31, 2013
					June 2013 Warrants [Member]	February 2011 Warrants [Member]	Warrants Classified as Equity [Member]	September 2010 Warrants [Member]	September 2010 Warrants [Member]	May 2009 Warrants [Member]	May 2009 Warrants [Member]
Note 9 - Warrants (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Class of Warrant or Right, Outstanding	8,230,848	'	8,230,848	'	'	'	'	'	'	'	'
Class of Warrant or Right, Number of Warrants Expired in Period	2,691,242	0	'	0	'	'	'	'	'	2,691,242	'
Class of Warrant or Right, Number of Warrants Exercises in Period	0	0	0	0	'	'	'	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	'	'	'	5,000,000	48,701	5,048,701	3,182,147	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	'	'	'	'	$5	$3.08	'	$4.24	$4.24	'	$3.74
Fair Value Measurements Sensitivity Analysis Percentage	'	'	10.00%	'	'	'	'	'	'	'	'
Fair Value Measurements Sensitivity Analysis Amount (in Dollars)	'	'	$0.10	'	'	'	'	'	'	'	'

Note_9_Warrants_Details_Estima

Note 9 - Warrants (Details) - Estimated Fair Value of Outstanding Warrants (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
September 2010 Warrants [Member]	'	'
Note 9 - Warrants (Details) - Estimated Fair Value of Outstanding Warrants [Line Items]	'	'
Exercise price (in Dollars per share)	$4.24	$4.24
Market value of stock at end of period (in Dollars per share)	$1.92	$1.76
Expected dividend rate	0.00%	0.00%
Expected volatility	68.30%	77.40%
Risk-free interest rate	0.10%	0.30%
Expected life (in years)	'1 year 10 days	'1 year 284 days
May 2009 Warrants [Member]	'	'
Note 9 - Warrants (Details) - Estimated Fair Value of Outstanding Warrants [Line Items]	'	'
Exercise price (in Dollars per share)	'	$3.74
Market value of stock at end of period (in Dollars per share)	'	$1.76
Expected dividend rate	'	0.00%
Expected volatility	'	45.30%
Risk-free interest rate	'	0.10%
Expected life (in years)	'	'146 days

Note_9_Warrants_Details_Change

Note 9 - Warrants (Details) - Change in Fair Value of the Warrant Liability (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Change in Fair Value of the Warrant Liability [Abstract]	'	'	'	'
Balance at beginning of period	$1,656	$1,951	$924	$3,251
Change in fair value of warrant liability included in:	'	'	'	'
Other expense (income)	-1,273	174	-541	-1,126
Balance at the end of period	$383	$2,125	$383	$2,125

Note_10_Sharebased_Compensatio2

Note 10 - Share-based Compensation (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Jun. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Jun. 03, 2010

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Begin to Vest [Member]

Options Granted Prior to January 2010 [Member]

Options Granted After January 2010 [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Maximum [Member]

Stock Option Plan [Member]

Restricted Share Unit Plan [Member]

Restricted Share Unit Plan [Member]

Restricted Share Unit Plan [Member]

Restricted Share Unit Plan [Member]

Restricted Share Unit Plan [Member]

Options Granted Prior to January 2010 [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Restricted Share Unit Plan [Member]

Stock Option Plan [Member]

Note 10 - Share-based Compensation (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum Fixed Reloading Percentage

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'1 year

'4 years

'36 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'

'

'8 years

'8 years

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

'

'

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Capital Shares Reserved for Future Issuance

'

'

'

'

9,155,597

'

9,155,597

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

'

'

2,998,360

'

2,998,360

'

'

'

530,910

'

'

530,910

'

640,910

'

640,910

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

'

'

104,000

10,000

185,500

10,000

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense (in Dollars)

'

'

'

'

$400,000

$400,000

$1,300,000

$1,300,000

'

'

($200,000)

$100,000

'

$400,000

$200,000

$19,103

$44,273

$83,633

$107,847

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

0

'

'

'

'

'

1,000

0

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

'

'

'

'

'

'

'

'

'

0

0

0

'

110,104

22,690

0

0

36,434

35,895

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

900,000

Employee Stock Purchase Plan Interval Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 months

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15.00%

'

15.00%

'

'

Employee Stock Purchase Plan Maximum Value Of Compensation Per Employee (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

Employee Stock Purchase Plan Purchase Of Common Stock Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85.00%

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000

'

'

Restricted Stock Unit, Shares Issued Per Unit Upon Conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

Restricted Share Units Maximum Shares Reserved

'

'

'

'

'

'

'

'

'

'

'

'

966,666

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

'

'

'

'

'

'

'

'

'

'

0

0

'

81,695

80,210

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

$250,000

$150,000

'

'

'

'

'

Value Shares Withheld Restricted Share Unit Percentage

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

'

'

'

'

'

'

'

Note_10_Sharebased_Compensatio3

Note 10 - Share-based Compensation (Details) - Weighted Average Assumptions (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Weighted Average Assumptions [Abstract]	'	'	'	'
Weighted average grant-date fair value for stock options granted (in Dollars per share)	$1.58	$1.27	$1.50	$1.27
Expected dividend rate	0.00%	0.00%	0.00%	0.00%
Expected volatility	82.02%	89.64%	75.10%	89.64%
Risk-free interest rate	1.91%	1.80%	1.42%	1.80%
Expected life of options (in years)	'6 years	'6 years	'4 years 215 days	'6 years

Note_12_Collaborative_and_Lice1

Note 12 - Collaborative and License Agreements (Details) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Sep. 30, 2014

Jun. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Upfront Payment [Member]

Array BioPharma Inc. [Member]

STC.UNM [Member]

STC.UNM [Member]

Merck KGaA [Member]

Merck KGaA [Member]

Merck KGaA [Member]

Merck KGaA [Member]

Array BioPharma Inc. [Member]

Note 12 - Collaborative and License Agreements (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Research and Development Expense

$5,663,000

$5,517,000

$15,876,000

$27,374,000

$10,000,000

'

'

'

'

'

'

'

Profit Share Percentage

'

'

'

'

'

50.00%

'

'

'

'

'

'

Number of Companies Sharing Proceeds From Sublicense of Marketing Rights

'

'

'

'

'

2

'

'

'

'

'

'

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners

'

'

'

'

'

'

'

5.00%

'

'

'

'

Contractual Obligation

'

'

'

'

'

'

97,000

'

'

'

'

'

Licenses Revenue

'

'

'

'

'

'

'

'

$0

$0

$0

$0

Note_13_Income_Tax_Details

Note 13 - Income Tax (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Income Tax Expense (Benefit)	$0	$0	$0	$0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	0	'	'	'
Deferred Tax Liabilities, Net	$6,900,000	'	$6,900,000	'
Effective Income Tax Rate Reconciliation, Percent	0.00%	'	'	'